IRONWOOD PHARMACEUTICALS INC (IRWD) Stock Price & Overview
NASDAQ:IRWD • US46333X1081
Current stock price
The current stock price of IRWD is 3.54 USD. Today IRWD is down by -9.23%. In the past month the price decreased by -2.21%. In the past year, price increased by 164.18%.
IRWD Key Statistics
- Market Cap
- 577.232M
- P/E
- 15.39
- Fwd P/E
- 3.00
- EPS (TTM)
- 0.23
- Dividend Yield
- N/A
IRWD Stock Performance
IRWD Stock Chart
IRWD Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to IRWD. When comparing the yearly performance of all stocks, IRWD is one of the better performing stocks in the market, outperforming 93.3% of all stocks.
IRWD Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to IRWD. IRWD has an excellent profitability rating, but there are some minor concerns on its financial health.
IRWD Earnings
On February 25, 2026 IRWD reported an EPS of -0.01 and a revenue of 47.71M. The company missed EPS expectations (-198.04% surprise) and missed revenue expectations (-8.17% surprise).
IRWD Forecast & Estimates
10 analysts have analysed IRWD and the average price target is 5.46 USD. This implies a price increase of 54.15% is expected in the next year compared to the current price of 3.54.
For the next year, analysts expect an EPS growth of 412.22% and a revenue growth 53.26% for IRWD
IRWD Groups
Sector & Classification
IRWD Financial Highlights
Over the last trailing twelve months IRWD reported a non-GAAP Earnings per Share(EPS) of 0.23. The EPS increased by 1050% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.11% | ||
| ROA | 6.05% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IRWD Ownership
IRWD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IRWD
Company Profile
Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2010-02-03. The company is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The firm is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Company Info
IPO: 2010-02-03
IRONWOOD PHARMACEUTICALS INC
100 Summer Street, Suite 2300
Boston MASSACHUSETTS 02110 US
CEO: Mark Mallon
Employees: 100
Phone: 16176217722
IRONWOOD PHARMACEUTICALS INC / IRWD FAQ
What does IRWD do?
Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2010-02-03. The company is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The firm is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Can you provide the latest stock price for IRONWOOD PHARMACEUTICALS INC?
The current stock price of IRWD is 3.54 USD. The price decreased by -9.23% in the last trading session.
Does IRWD stock pay dividends?
IRWD does not pay a dividend.
What is the ChartMill technical and fundamental rating of IRWD stock?
IRWD has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What do analysts say about IRONWOOD PHARMACEUTICALS INC (IRWD) stock?
10 analysts have analysed IRWD and the average price target is 5.46 USD. This implies a price increase of 54.15% is expected in the next year compared to the current price of 3.54.
Would investing in IRONWOOD PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IRWD.
Can you provide the upcoming earnings date for IRONWOOD PHARMACEUTICALS INC?
IRONWOOD PHARMACEUTICALS INC (IRWD) will report earnings on 2026-05-05.